ClinicalTrials.gg
CompletedNCT04091451Updated Dec 4, 2025Results posted

Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster

A Phase 3 interventional study of Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 3 sites in Russia. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,430
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
9th of 46
1,430 · median 239
Started
2019
with 4 others
Phase 3
22 of 46
2 open now
Registered
27th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 9th largest by enrollment, is one of 5 that started in 2019, is one of 22 in phase 3, and was the 27th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Shingles
  • Shingles recurrence
  • HZ
  • Vaccine response rate
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects and/or subject's LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol
  • Written obtained from the subject/subject's LAR(s) prior to performance of any study specific procedure.
  • A male or female ≥ 50 YOA at the time of the first vaccination.
  • Subjects with a history of HZ. Confirmation of the prior HZ diagnosis can be done by one of the following three methods:

    • Clinically diagnosed HZ:

OR Laboratory diagnosed HZ: OR

  • HZ diagnosed by an adjudication committee: Female subjects of non- may be enrolled in the study.
  • Non-childbearing potential is defined as current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, bilateral salpingectomy or .

    • Female subjects of childbearing potential may be enrolled in the study if the subject:
  • has practiced adequate for 30 days prior to vaccination, and
  • has a negative pregnancy test on the day of vaccination, and
  • has agreed to continue adequate contraception for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Subjects who at time of study entry or during the maximum period of anticipated study participation are/will become part of the population recommended to receive a zoster vaccine per existing local or national immunization practices will be excluded from study participation.
  • Use of any or non-registered product other than the study vaccine during the period starting 30 days before the first dose of study vaccine, or planned use during the study period.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Onset of HZ in the past 6 months or any ongoing symptoms from a prior HZ episode.
  • Chronic antiviral use for HZ prophylaxis.
  • History of >1 prior episode of HZ.
  • A history of disseminated HZ, cutaneous or associated with visceral disease or associated with neurologic disease caused by VZV infection.
  • Use or anticipated use of or immune-modifying drugs during the period starting six months prior to study start and during the whole study period. This includes chronic administration of , long-acting immune-modifying agents or immunosuppressive/cytotoxic therapy
  • Administration or planned administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine. However, licensed pneumococcal vaccines and non-replicating vaccines may be administered up until 8 days prior to dose 1 and/or dose 2 and/or at least 14 days after any dose of study vaccine.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product
  • Previous vaccination against VZV or HZ.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Acute disease and/or fever at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions in the period up to 2 months after completion of the vaccination series.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,430 participants (actual)

Study arms

  • Experimental
    HZ/su Group

    Participants with a prior episode of HZ randomized to the HZ/su group were scheduled to receive 2 doses of HZ/su vaccine, one at Day 1 and one at Month 2.

    Biological: Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)

  • Placebo comparator
    Placebo Group

    Participants with a prior episode of HZ randomized to the Placebo group were scheduled to receive 2 doses of placebo, one at Day 1 and one at Month 2.

    Drug: Placebo

Interventions

  • BiologicalHerpes Zoster subunit (HZ/su) vaccine (GSK1437173A)

    Drug page: Shingrix

    2 doses of HZ/su vaccine were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.

  • DrugPlacebo

    2 doses of Placebo were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.

06

What researchers measure

Primary outcomes

  1. Incidence Rate of Confirmed Herpes Zoster (HZ) Cases

    A suspected case of HZ is defined as a new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ was confirmed by an algorithm that included Polymerase Chain Reaction (PCR) and the HZ Ascertainment Committee (HZAC) determination. The incidence rate (n/T) of confirmed HZ cases, expressed in terms of 1000 person-years rate, was calculated as the number of participants reporting at least one confirmed HZ case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 1000.

    Time frame: From 30 days post-second vaccination (Month 3) until study end (duration of approximately 2 years to 4 years and 5 months)

Secondary outcomes

  1. Incidence Rate of Confirmed HZ Cases

    A suspected case of HZ is defined as a new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ was confirmed by an algorithm that included PCR and the HZAC determination. The incidence rate (n/T) of confirmed HZ cases, expressed in terms of 1000 person-years rate, was calculated as the number of participants reporting at least one confirmed HZ case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 1000.

    Time frame: From first vaccination (Day 1) until study end (duration of approximately 2 years to 4 years and 5 months)

  2. Number of Participants With Any and Grade 3 Solicited Administration Site Events

    Assessed solicited administration site events included erythema, pain, pruritus and swelling at the injection site. Any = occurrence of the event regardless of intensity grade. Grade 3 pain = significant pain at rest, which prevented normal, everyday activities. Grade 3 erythema, swelling = erythema, swelling with a surface diameter greater than (\>) 100 millimeters (mm). Grade 3 pruritus = itchy sensation that prevented normal, everyday activities.

    Time frame: Within 7 days after each vaccination (occurring at Day 1 and Month 2)

  3. Duration in Days of Solicited Administration Site Events

    Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. Assessed solicited administration site events included erythema, pain, pruritus and swelling at the injection site.

    Time frame: Within 7 days after each vaccination (occurring at Day 1 and Month 2)

  4. Number of Participants With Any, Grade 3 and Related Solicited Systemic Events

    Assessed solicited systemic events included fatigue, fever (defined as axillary temperature greater than or equal to (\>=) 38.0°C/100.4°F), gastrointestinal symptoms, headache, malaise, myalgia, and shivering. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination. Grade 3 = event that prevented normal, everyday activities. Grade 3 fever = axillary temperature higher than (\>) 39.0°C/102.2°F. Related = event assessed by the investigator as related to the study vaccination.

    Time frame: Within 7 days after each vaccination (occurring at Day 1 and Month 2)

  5. Duration in Days of Solicited Systemic Events

    Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. Assessed solicited systemic events included fatigue, fever (defined as axillary temperature \>=38.0°C/100.4°F), gastrointestinal symptoms, headache, malaise, myalgia and shivering.

    Time frame: Within 7 days after each vaccination (occurring at Day 1 and Month 2)

  6. Number of Participants With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Any = occurrence the event regardless of intensity grade or relation to the study vaccination. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as related to the study vaccination.

    Time frame: Within 30 days after each vaccination (occurring at Day 1 and Month 2)

  7. Number of Participants With Any and Related Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. Related = SAE assessed by the investigator as related to the study vaccination.

    Time frame: From first vaccination (Day 1) to 30 days post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)

  8. Number of Participants With Any and Related Potential Immune-mediated Diseases (pIMDs)

    pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination. Related = pIMD assessed by the investigator as related to the study vaccination.

    Time frame: From first vaccination (Day 1) to 30 days post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)

  9. Number of Participants With Any and Related SAEs

    An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. Related = SAE assessed by the investigator as related to the study vaccination.

    Time frame: From 30 days post-last vaccination until 1 year post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)

  10. Number of Participants With Any and Related pIMDs

    pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination. Related = pIMD assessed by the investigator as related to the study vaccination.

    Time frame: From 30 days post-last vaccination until 1 year post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)

  11. Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine

    An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any SAEs related to the investigational vaccine or related to study participation or to a GSK concomitant medication/vaccine as assessed by the investigator are reported.

    Time frame: From first vaccination (Day 1) until study end (duration of approximately 2 years to 4 years and 5 months)

  12. Percentage of Participants With Vaccine Response for Anti-glycoprotein E (Anti-gE) Antibodies as Determined by Enzyme Linked Immunosorbent Assay (ELISA)

    Vaccine response for anti-gE antibodies is defined as: * For initially seronegative participants, anti-gE antibody concentration at post-vaccination \>= 4-fold the cut-off value for anti-gE \[97 international units per liter (IU/L)\]. * For initially seropositive participants, anti-gE antibody concentration at post-vaccination \>= 4-fold the pre-vaccination anti-gE antibody concentration.

    Time frame: At Month 2 and Month 3

  13. Anti-gE Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) as Determined by ELISA

    Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in IU/L.

    Time frame: At Day 1, Month 2 and Month 3

07

Results

Posted Mar 30, 2025

Participant flow

The study was conducted at 46 centers in 8 countries (Estonia, Finland, Hong Kong, Mexico, Panama, Russian Federation, Spain and United Kingdom).

Participant flow — Overall Study
MilestoneHZ/su GroupPlacebo Group
Started714712
Completed646640
Not completed6872
Withdrew: Adverse event1510
Withdrew: Lost to follow-up88
Withdrew: Protocol violation54
Withdrew: Withdrawal by subject2127
Withdrew: Non-emergency unblinding/non-compliance1518
Withdrew: Migrated/moved from the study area35
Withdrew: Suspected hz episode10

Outcome measures

PrimaryIncidence Rate of Confirmed Herpes Zoster (HZ) Cases

A suspected case of HZ is defined as a new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ was confirmed by an algorithm that included Polymerase Chain Reaction (PCR) and the HZ Ascertainment Committee (HZAC) determination. The incidence rate (n/T) of confirmed HZ cases, expressed in terms of 1000 person-years rate, was calculated as the number of participants reporting at least one confirmed HZ case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 1000.

Time frame:
From 30 days post-second vaccination (Month 3) until study end (duration of approximately 2 years to 4 years and 5 months)
Reported as:
Number · Cases per 1000 person-years
Incidence Rate of Confirmed Herpes Zoster (HZ) Cases
Cases per 1000 person-yearsHZ/su GroupPlacebo Group
Incidence Rate of Confirmed Herpes Zoster (HZ) Cases0.04.1
Statistical analysis
  • HZ/su Group vs Placebo Group · Poisson · Incidence rate ratio (irr): 0.00 · 95% CI 0.00 to 0.46IRR = incidence rate of HZ recurrence in HZ/su group divided by the incidence rate of HZ recurrence in Placebo group. Poisson method was used to adjust for differences in follow-up time across individuals.
SecondaryIncidence Rate of Confirmed HZ Cases

A suspected case of HZ is defined as a new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ was confirmed by an algorithm that included PCR and the HZAC determination. The incidence rate (n/T) of confirmed HZ cases, expressed in terms of 1000 person-years rate, was calculated as the number of participants reporting at least one confirmed HZ case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 1000.

Time frame:
From first vaccination (Day 1) until study end (duration of approximately 2 years to 4 years and 5 months)
Reported as:
Number · Cases per 1000 person-years
Incidence Rate of Confirmed HZ Cases
Cases per 1000 person-yearsHZ/su GroupPlacebo Group
Incidence Rate of Confirmed HZ Cases0.03.6
SecondaryNumber of Participants With Any and Grade 3 Solicited Administration Site Events

Assessed solicited administration site events included erythema, pain, pruritus and swelling at the injection site. Any = occurrence of the event regardless of intensity grade. Grade 3 pain = significant pain at rest, which prevented normal, everyday activities. Grade 3 erythema, swelling = erythema, swelling with a surface diameter greater than (\>) 100 millimeters (mm). Grade 3 pruritus = itchy sensation that prevented normal, everyday activities.

Time frame:
Within 7 days after each vaccination (occurring at Day 1 and Month 2)
Reported as:
Count of participants · Participants
Number of Participants With Any and Grade 3 Solicited Administration Site Events
ParticipantsHZ/su GroupPlacebo Group
Any Erythema, post-vaccination at Day 11645
Grade 3 Erythema, post-vaccination at Day 180
Any Pain, post-vaccination at Day 156261
Grade 3 Pain, post-vaccination at Day 1492
Any Pruritus, post-vaccination at Day 114824
Grade 3 Pruritus, post-vaccination at Day 140
Any Swelling, post-vaccination at Day 1911
Grade 3 Swelling, post-vaccination at Day 130
Any Erythema, post-vaccination at Month 21640
Grade 3 Erythema, post-vaccination at Month 2140
Any Pain, post-vaccination at Month 250348
Grade 3 Pain, post-vaccination at Month 2480
Any Pruritus, post-vaccination at Month 214210
Grade 3 Pruritus, post-vaccination at Month 270
Any Swelling, post-vaccination at Month 2821
Grade 3 Swelling, post-vaccination at Month 230
SecondaryDuration in Days of Solicited Administration Site Events

Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. Assessed solicited administration site events included erythema, pain, pruritus and swelling at the injection site.

Time frame:
Within 7 days after each vaccination (occurring at Day 1 and Month 2)
Reported as:
Median · Days
Duration in Days of Solicited Administration Site Events
DaysHZ/su GroupPlacebo Group
Erythema, post-vaccination at Day 13.0 (2.0 to 5.0)3.0 (2.0 to 4.0)
Pain, post-vaccination at Day 13.0 (2.0 to 4.0)1.0 (1.0 to 2.0)
Pruritus, post-vaccination at Day 12.0 (1.0 to 3.0)1.0 (1.0 to 3.0)
Swelling, post-vaccination at Day 13.0 (1.0 to 4.0)2.0 (2.0 to 2.0)
Erythema, post-vaccination at Month 23.0 (2.0 to 5.0)—
Pain, post-vaccination at Month 23.0 (2.0 to 4.0)1.0 (1.0 to 2.0)
Pruritus, post-vaccination at Month 22.0 (1.0 to 3.0)1.0 (1.0 to 2.0)
Swelling, post-vaccination at Month 23.0 (2.0 to 4.0)6.0 (6.0 to 6.0)
SecondaryNumber of Participants With Any, Grade 3 and Related Solicited Systemic Events

Assessed solicited systemic events included fatigue, fever (defined as axillary temperature greater than or equal to (\>=) 38.0°C/100.4°F), gastrointestinal symptoms, headache, malaise, myalgia, and shivering. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination. Grade 3 = event that prevented normal, everyday activities. Grade 3 fever = axillary temperature higher than (\>) 39.0°C/102.2°F. Related = event assessed by the investigator as related to the study vaccination.

Time frame:
Within 7 days after each vaccination (occurring at Day 1 and Month 2)
Reported as:
Count of participants · Participants
Number of Participants With Any, Grade 3 and Related Solicited Systemic Events
ParticipantsHZ/su GroupPlacebo Group
Any Fatigue, post-vaccination at Day 1329146
Grade 3 Fatigue, post-vaccination at Day 14210
Related Fatigue, post-vaccination at Day 1292105
Any Fever, post-vaccination at Day 1264
Grade 3 Fever, post-vaccination at Day 110
Related Fever, post-vaccination at Day 1264
Any Gastrointestinal symptoms, post-vaccination at Day 110379
Grade 3 Gastrointestinal symptoms, post-vaccination at Day 184
Related Gastrointestinal symptoms, post-vaccination at Day 18454
Any Headache, post-vaccination at Day 1266136
Grade 3 Headache, post-vaccination at Day 12111
Related Headache, post-vaccination at Day 122490
Any Malaise, post-vaccination at Day 126070
Grade 3 Malaise, post-vaccination at Day 1309
Related Malaise, post-vaccination at Day 123152
Any Myalgia, post-vaccination at Day 126265
Grade 3 Myalgia, post-vaccination at Day 1178
Related Myalgia, post-vaccination at Day 124045
Any Shivering, post-vaccination at Day 118543
Grade 3 Shivering, post-vaccination at Day 1160
Related Shivering, post-vaccination at Day 117436
Any Fatigue, post-vaccination at Month 2364115
Grade 3 Fatigue, post-vaccination at Month 25910
Related Fatigue, post-vaccination at Month 232785
Any Fever, post-vaccination at Month 2665
Grade 3 Fever, post-vaccination at Month 241
Related Fever, post-vaccination at Month 2633
Any Gastrointestinal symptoms, post-vaccination at Month 211854
Grade 3 Gastrointestinal symptoms, post-vaccination at Month 2114
Related Gastrointestinal symptoms, post-vaccination at Month 210237
Any Headache, post-vaccination at Month 2290113
Grade 3 Headache, post-vaccination at Month 2306
Related Headache, post-vaccination at Month 225673
Any Malaise, post-vaccination at Month 232169
Grade 3 Malaise, post-vaccination at Month 2457
Related Malaise, post-vaccination at Month 229050
Any Myalgia, post-vaccination at Month 229454
Grade 3 Myalgia, post-vaccination at Month 2412
Related Myalgia, post-vaccination at Month 226940
Any Shivering, post-vaccination at Month 225332
Grade 3 Shivering, post-vaccination at Month 2372
Related Shivering, post-vaccination at Month 223428
SecondaryDuration in Days of Solicited Systemic Events

Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. Assessed solicited systemic events included fatigue, fever (defined as axillary temperature \>=38.0°C/100.4°F), gastrointestinal symptoms, headache, malaise, myalgia and shivering.

Time frame:
Within 7 days after each vaccination (occurring at Day 1 and Month 2)
Reported as:
Median · Days
Duration in Days of Solicited Systemic Events
DaysHZ/su GroupPlacebo Group
Fatigue, post-vaccination at Day 12.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
Fever, post-vaccination at Day 11.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Gastrointestinal symptoms, post-vaccination at Day 11.0 (1.0 to 3.0)2.0 (1.0 to 2.0)
Headache, post-vaccination at Day 12.0 (1.0 to 3.0)1.0 (1.0 to 3.0)
Malaise, post-vaccination at Day 12.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
Myalgia, post-vaccination at Day 12.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
Shivering, post-vaccination at Day 11.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Fatigue, post-vaccination at Month 22.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
Fever, post-vaccination at Month 21.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
Gastrointestinal symptoms, post-vaccination at Month 22.0 (1.0 to 3.0)1.0 (1.0 to 2.0)
Headache, post-vaccination at Month 22.0 (1.0 to 3.0)2.0 (1.0 to 2.0)
Malaise, post-vaccination at Month 22.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
Myalgia, post-vaccination at Month 22.0 (1.0 to 3.0)2.0 (1.0 to 5.0)
Shivering, post-vaccination at Month 21.0 (1.0 to 2.0)2.0 (1.0 to 3.0)
SecondaryNumber of Participants With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Any = occurrence the event regardless of intensity grade or relation to the study vaccination. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as related to the study vaccination.

Time frame:
Within 30 days after each vaccination (occurring at Day 1 and Month 2)
Reported as:
Count of participants · Participants
Number of Participants With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsHZ/su GroupPlacebo Group
Any Unsolicited AEs, post-vaccination at Day 1118104
Grade 3 Unsolicited AEs, post-vaccination at Day 11210
Related Unsolicited AEs, post-vaccination at Day 13218
Any Unsolicited AEs, post-vaccination at Month 2120116
Grade 3 Unsolicited AEs, post-vaccination at Month 2136
Related Unsolicited AEs, post-vaccination at Month 2337
SecondaryNumber of Participants With Any and Related Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. Related = SAE assessed by the investigator as related to the study vaccination.

Time frame:
From first vaccination (Day 1) to 30 days post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)
Reported as:
Count of participants · Participants
Number of Participants With Any and Related Serious Adverse Events (SAEs)
ParticipantsHZ/su GroupPlacebo Group
Any SAEs1111
Related SAEs00
SecondaryNumber of Participants With Any and Related Potential Immune-mediated Diseases (pIMDs)

pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination. Related = pIMD assessed by the investigator as related to the study vaccination.

Time frame:
From first vaccination (Day 1) to 30 days post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)
Reported as:
Count of participants · Participants
Number of Participants With Any and Related Potential Immune-mediated Diseases (pIMDs)
ParticipantsHZ/su GroupPlacebo Group
Any pIMDs22
Related pIMDs01
SecondaryNumber of Participants With Any and Related SAEs

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. Related = SAE assessed by the investigator as related to the study vaccination.

Time frame:
From 30 days post-last vaccination until 1 year post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)
Reported as:
Count of participants · Participants
Number of Participants With Any and Related SAEs
ParticipantsHZ/su GroupPlacebo Group
Any SAEs3522
Related SAEs00
SecondaryNumber of Participants With Any and Related pIMDs

pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination. Related = pIMD assessed by the investigator as related to the study vaccination.

Time frame:
From 30 days post-last vaccination until 1 year post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)
Reported as:
Count of participants · Participants
Number of Participants With Any and Related pIMDs
ParticipantsHZ/su GroupPlacebo Group
Any pIMDs25
Related pIMDs00
SecondaryNumber of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any SAEs related to the investigational vaccine or related to study participation or to a GSK concomitant medication/vaccine as assessed by the investigator are reported.

Time frame:
From first vaccination (Day 1) until study end (duration of approximately 2 years to 4 years and 5 months)
Reported as:
Count of participants · Participants
Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine
ParticipantsHZ/su GroupPlacebo Group
Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine11
SecondaryPercentage of Participants With Vaccine Response for Anti-glycoprotein E (Anti-gE) Antibodies as Determined by Enzyme Linked Immunosorbent Assay (ELISA)

Vaccine response for anti-gE antibodies is defined as: * For initially seronegative participants, anti-gE antibody concentration at post-vaccination \>= 4-fold the cut-off value for anti-gE \[97 international units per liter (IU/L)\]. * For initially seropositive participants, anti-gE antibody concentration at post-vaccination \>= 4-fold the pre-vaccination anti-gE antibody concentration.

Time frame:
At Month 2 and Month 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Vaccine Response for Anti-glycoprotein E (Anti-gE) Antibodies as Determined by Enzyme Linked Immunosorbent Assay (ELISA)
Percentage of participantsHZ/su GroupPlacebo Group
At Month 285.8 (82.8 to 88.5)0.2 (0.0 to 0.9)
At Month 395.3 (93.1 to 96.9)0.2 (0.0 to 1.1)
SecondaryAnti-gE Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) as Determined by ELISA

Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in IU/L.

Time frame:
At Day 1, Month 2 and Month 3
Reported as:
Geometric mean · IU/L
Anti-gE Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) as Determined by ELISA
IU/LHZ/su GroupPlacebo Group
At Day 12151.30 (2004.22 to 2309.17)2087.14 (1942.47 to 2242.58)
At Month 224346.52 (22840.59 to 25951.74)1850.11 (1725.86 to 1983.30)
At Month 349175.78 (46500.40 to 52005.09)1849.08 (1718.02 to 1990.13)

Adverse events

Collected over Solicited AEs: within 7 days after any vaccination. Unsolicited AEs: within 30 days after any vaccination. All-cause mortality & SAEs: from first vaccination (Day 1) until study end (duration of approximately 2 years to 4 years and 5 months). pIMDs: from first vaccination (Day 1) until 1 year post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HZ/su Group12/714 (1.7%)56/714 (7.8%)665/714 (93.1%)
Placebo Group8/712 (1.1%)43/712 (6%)414/712 (58.1%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventHZ/su GroupPlacebo Group
COVID-19 pneumoniaInfections and infestations4/7145/712
PneumoniaInfections and infestations4/7142/712
COVID-19Infections and infestations3/7141/712
Cardiac failureCardiac disorders2/7142/712
Myocardial infarctionCardiac disorders2/7142/712
OsteoarthritisMusculoskeletal and connective tissue disorders0/7142/712
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/7142/712
Ischaemic strokeNervous system disorders0/7142/712
Cardiac arrestCardiac disorders2/7141/712
CellulitisInfections and infestations2/7140/712
Most frequent other events
Showing 10 of 264
Most frequent other events
EventHZ/su GroupPlacebo Group
Administration site painGeneral disorders611/71494/712
FatigueGeneral disorders457/714199/712
MalaiseGeneral disorders396/714112/712
MyalgiaMusculoskeletal and connective tissue disorders389/71497/712
HeadacheNervous system disorders384/714201/712
ChillsGeneral disorders330/71464/712
Administration site erythemaGeneral disorders238/7145/712
PruritusSkin and subcutaneous tissue disorders228/71433/712
Gastrointestinal disorderGastrointestinal disorders179/714117/712
Administration site swellingGeneral disorders133/7142/712

Baseline characteristics

Age, Continuous
Age, Continuous(Years)HZ/su GroupPlacebo GroupTotal
Mean64.2 ± 8.564.1 ± 8.864.1 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)HZ/su GroupPlacebo GroupTotal
Female430434864
Male284278562
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HZ/su GroupPlacebo GroupTotal
Hispanic or Latino8077157
Not Hispanic or Latino6346351269
Unknown or Not Reported000
08

Study locations

3 sites
  • GSK Investigational Site
    Barnaul, 656043, Russia
  • GSK Investigational Site
    Gatchina, 188300, Russia
  • GSK Investigational Site
    Moscow, 115478, Russia
09

References and documents

Publications

  • Jegede B, Zhou Y, Hawksworth H, Hui DSC, Montenegro Guerra N, Poder A, Ramon JM, Valimaa H, Villanueva-Quintero GD, Mwakingwe-Omari A; Z-062 study group. Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged >/=50 years with a history of herpes zoster: A phase 3, randomized controlled trial. J Infect. 2025 Sep;91(3):106573. doi: 10.1016/j.jinf.2025.106573. Epub 2025 Aug 6. PubMed 40780591 ↗
  • de Oliveira Gomes J, Gagliardi AM, Andriolo BN, Torloni MR, Andriolo RB, Puga MEDS, Canteiro Cruz E. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD008858. doi: 10.1002/14651858.CD008858.pub5. PubMed 37781954 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Feb 2024, 52 months.

Results were first posted in Mar 2025, 1 year 1 month after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 52 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2019
First posted
Sep 16, 2019
StartActual
Sep 17, 2019
Primary completionActual
Feb 15, 2024
CompletionActual
Feb 15, 2024
Results first posted
Mar 30, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04091451
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 16, 2019
Start date
Sep 17, 2019
Primary completion
Feb 15, 2024
Completion
Feb 15, 2024
Results posted
Mar 30, 2025
Last update
Dec 4, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion